@article{
 title = {RNAi Therapeutics: Principles, Prospects and Challenges},
 type = {article},
 year = {2007},
 identifiers = {[object Object]},
 pages = {75-86},
 volume = {59},
 websites = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978219/},
 month = {3},
 day = {30},
 id = {1f7feb5d-bb1f-3808-a2ae-0da3da5d4662},
 created = {2015-06-04T11:15:50.000Z},
 file_attached = {false},
 profile_id = {9a79eba8-0be6-3f31-a330-c23bdcc451dc},
 group_id = {0e532975-1a47-38a4-ace8-4fe5968bcd72},
 last_modified = {2015-06-04T11:15:50.000Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 source_type = {JOUR},
 abstract = {RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. },
 bibtype = {article},
 author = {Aagaard, Lars and Rossi, John J},
 journal = {Advanced drug delivery reviews},
 number = {2-3}
}

{"_id":"ERKpeM5CWmiGi9jmG","bibbaseid":"aagaard-rossi-rnaitherapeuticsprinciplesprospectsandchallenges-2007","downloads":0,"creationDate":"2015-08-05T17:19:31.519Z","title":"RNAi Therapeutics: Principles, Prospects and Challenges","author_short":["Aagaard, L.","Rossi, J., J."],"year":2007,"bibtype":"article","biburl":null,"bibdata":{"title":"RNAi Therapeutics: Principles, Prospects and Challenges","type":"article","year":"2007","identifiers":"[object Object]","pages":"75-86","volume":"59","websites":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978219/","month":"3","day":"30","id":"1f7feb5d-bb1f-3808-a2ae-0da3da5d4662","created":"2015-06-04T11:15:50.000Z","file_attached":false,"profile_id":"9a79eba8-0be6-3f31-a330-c23bdcc451dc","group_id":"0e532975-1a47-38a4-ace8-4fe5968bcd72","last_modified":"2015-06-04T11:15:50.000Z","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"source_type":"JOUR","abstract":"RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. ","bibtype":"article","author":"Aagaard, Lars and Rossi, John J","journal":"Advanced drug delivery reviews","number":"2-3","bibtex":"@article{\n title = {RNAi Therapeutics: Principles, Prospects and Challenges},\n type = {article},\n year = {2007},\n identifiers = {[object Object]},\n pages = {75-86},\n volume = {59},\n websites = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978219/},\n month = {3},\n day = {30},\n id = {1f7feb5d-bb1f-3808-a2ae-0da3da5d4662},\n created = {2015-06-04T11:15:50.000Z},\n file_attached = {false},\n profile_id = {9a79eba8-0be6-3f31-a330-c23bdcc451dc},\n group_id = {0e532975-1a47-38a4-ace8-4fe5968bcd72},\n last_modified = {2015-06-04T11:15:50.000Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n source_type = {JOUR},\n abstract = {RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. },\n bibtype = {article},\n author = {Aagaard, Lars and Rossi, John J},\n journal = {Advanced drug delivery reviews},\n number = {2-3}\n}","author_short":["Aagaard, L.","Rossi, J., J."],"bibbaseid":"aagaard-rossi-rnaitherapeuticsprinciplesprospectsandchallenges-2007","role":"author","urls":{},"downloads":0,"html":""},"search_terms":["rnai","therapeutics","principles","prospects","challenges","aagaard","rossi"],"keywords":[],"authorIDs":[]}